Eli Lilly (LLY) Eyes First Oral OSA Approval After Phase 3 Foundayo Win

Simply Wall St.08:42

Eli Lilly (NYSE: LLY) reported that oral obesity drug Foundayo (orforglipron) produced significant benefits in a large Phase 3 OSA trial. The study showed meaningful improvements in obstructive sleep ...

Source Link
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment